Postoperative chemoradiotherapy for esophageal squamous cell Carcinoma: Results from ESO-Shanghai 17 and joint analyses for phase II clinical trials.

Clin Transl Radiat Oncol · 2026 · PMC12794425 · PMID 41531940

Europe PMC DOI

hedged sentence

0.1064

closest p · 2.1× alpha

0.1064

boldest claim

The sentences

did not reach statistical significanceP = 0.1064not close (p > 0.1)

Although the median overall survival was longer in the nivolumab group, this difference did not reach statistical significance (P = 0.1064)[ 31 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.